- |||||||||| micronized fenofibrate / Generic mfg., fenofibrate / Generic mfg.
Biomarker, Enrollment open: Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - Feb 6, 2019
P4, N=40, Recruiting,
Not yet recruiting --> Recruiting
- |||||||||| micronized fenofibrate / Generic mfg., fenofibrate / Generic mfg.
Biomarker, New P4 trial: Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - Feb 4, 2019
P4, N=40, Not yet recruiting,
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. (Pubmed Central) - Jan 1, 2019
There was no difference in incidence of CKD (HR 0.92, 95% CI 0.74-1.15, P = 0.46) and/or kidney failure (HR 0.95, 95% CI 0.68-1.33, P = 0.76). Compared with placebo, randomization to fenofibrate was associated with lower rates of incident albuminuria and a slower eGFR decline, but no difference in incidence of CKD or kidney failure in ACCORD participants.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Trial completion, Trial completion date: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Jun 13, 2018
P=N/A, N=114, Completed,
Compared with placebo, randomization to fenofibrate was associated with lower rates of incident albuminuria and a slower eGFR decline, but no difference in incidence of CKD or kidney failure in ACCORD participants. Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Feb 2018
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Enrollment closed: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Jan 8, 2018
P=N/A, N=114, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Feb 2018 Recruiting --> Active, not recruiting
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Xenical (orlistat) / Roche, GSK
Journal: Type 1 hyperlipoproteinemia in a child with large homozygous deletion encompassing GPIHBP1. (Pubmed Central) - Oct 12, 2017
Extreme hypertriglyceridemia failed to respond to treatment with fenofibrate, fish oil, and orlistat...We highlight the need to perform copy number variations analysis of whole-exome sequencing data for finding disease-causing variants. There is also an urgent need to develop novel targeted therapies for patients with T1HLP.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Trial primary completion date: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=104, Recruiting,
There is also an urgent need to develop novel targeted therapies for patients with T1HLP. Trial primary completion date: Mar 2017 --> Feb 2018
- |||||||||| micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Trial termination: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014
P4, N=41, Terminated,
Trial primary completion date: Mar 2017 --> Feb 2018 Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up
- |||||||||| micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Enrollment change: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014
P4, N=41, Terminated,
Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up N=80 --> 41
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Enrollment open: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=104, Recruiting,
N=80 --> 41 Not yet recruiting --> Recruiting
|
